Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL6465998 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL396231 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41204 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL4016537 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8025793 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL2412146 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL7204032 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18948 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41203 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18949 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116262712-A | Impurities of lisdexamphetamine dimesylate, and preparation method and application thereof | 四川科瑞德制药股份有限公司 | 2023-06-16 | — | — | CN | claimed |
| WO-2022040768-A1 | COMPOSITIONS FOR USES IN METHODS OF TREATING CORONAVIRUS INFECTIONS | NOWILL ALEXANDRE EDUARDO (BR) | 2022-03-03 | — | — | WO | claimed |
| US-12491216-B2 | Immunostimulant for use against pathogens | NEIKER—INSTITUTO VASCO DE INVESTIGACION Y DESARROLLO AGRARIO, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12006275-B2 | Process for making levoamphetamine | Pharmapotheca A, Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3890759-B1 | IMMUNOSTIMULANT FOR USE AGAINST PATHOGENS | SABIOTEC SPIN OFF S L (ES) | 2023-08-23 | — | — | EP | disclosed |
| CN-116262712-A | Impurities of lisdexamphetamine dimesylate, and preparation method and application thereof | 四川科瑞德制药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20220162153-A1 | Process for Making Levoamphetamine | Pharmapotheca A, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2022040768-A1 | COMPOSITIONS FOR USES IN METHODS OF TREATING CORONAVIRUS INFECTIONS | NOWILL ALEXANDRE EDUARDO (BR) | 2022-03-03 | — | — | WO | disclosed |
| US-20220054557-A1 | IMMUNOSTIMULANT FOR USE AGAINST PATHOGENS | NEIKER - Instituto Vasco de Investigacion y Desarrollo Agrario, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| US-20140194524-A1 | Methods for Treating Alzheimer's Disease | COGNITION PHARMACEUTICALS, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20040220277-A1 | Enantiomeric amphetamine compositions | SHIRE CANADA INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| WO-2004071501-A1 | ENANTIOMERIC AMPHETAMINE COMPOSITIONS FOR THE TREATMENT OF ADHD | SHIRE BIOCHEM INC. (CA) | 2004-08-26 | — | — | WO | disclosed |
| US-6265615-B1 | DISSOLVING POLYMER IN ORGANIC SOLVENT ALONG WITH CHIRAL DOPANT TO FORM CHIRAL DOPED POLYMER SOLUTION, REMOVING SOLVENT TO FORM DOPED POLYMERIC MATERIAL; REMOVING CHIRAL DOPANT FROM DOPED POLYMERIC MATERIAL TO FORM A DEDOPED POLYMERIC MATERIAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-07-24 | — | — | US | disclosed |
| WO-2000001642-A1 | CHIRAL RECOGNITION POLYMER AND ITS USE TO SEPARATE ENANTIOMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0390112-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5391739-A | Adenosine antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5329007-A | Selective adenosine receptor agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-07-12 | — | — | US | disclosed |
| US-5256650-A | Hypotensive, antispasmodic agents; sedatives; vasodilation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0390112-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194524-A1 | Methods for Treating Alzheimer's Disease | CHAT, ACHE, PNMT | SLC6A2 10/4885SLC6A3 25/4885TAAR1 74/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885SLC6A3 1/4885TAAR1 37/4885 |
| US-20220162153-A1 | Process for Making Levoamphetamine | COMT, PNMT, MAOA | SLC6A2 7/4885SLC6A3 13/4885TAAR1 82/4885 |
| US-12006275-B2 | Process for making levoamphetamine | COMT, PNMT, MAOA | SLC6A2 7/4885SLC6A3 13/4885TAAR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.